Should the antipapillomavirus vaccination after the age of 25 be advised?;Place de la vaccination antipapillomavirus après 25 ans

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 37, Issue 8, 2008, Pages 748-752

  Simon, P ^a   Poppe, W ^b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

HPV; Mature women; Vaccination

Indexed keywords

WART VIRUS VACCINE;

HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; PREVALENCE; PROPHYLAXIS; REPRODUCTIVE HEALTH; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; REPRODUCTIVE HISTORY; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 57049144803     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2008.07.003     Document Type: Review

References (23)

1. ESGO Statement on Cervical Cancer Vaccination Int J Gynecol Cancer 2007; 17:1183-85.
2. Flemish Cancer Registry Network (E. Van Eycken et al.: Cancer Incidence and survival in Flanders, 2006, VLK, Brussels).
3. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 370 9580 (2007) 2161-2170
4. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356;19 1915-27.
5. Dunne E.F., Unger E.R., Sternberg M., Mc Quillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc 297 (2007) 813-819
6. Grainge M.J., Seth R., Neal K.R., Coupland C., Vryenhoef P., Johnson J., et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 11 (2005) 1680-1685
7. Burchell A.N., Richardson H., Mahmud S.M., Trottier H., Tellier P.P., Hanley J., et al. Modelling the sexual transmissibility of human papillomavirus infection using stochatic computer simulation and empirical data from a cohort study of young women in Montreal Canada. Am J Epidemiol 163 (2006) 534-543
8. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. JID 191 (2005) 1808-1816
9. Coupé VMH, Berkhof J, Bulkmans NWJ Snijders PJ, Meijer CJ. Age dependent prevalence of 14 high risk HPV types in the Netherlands: implications for prophylactic vaccinationand screening. B J Cancer 2008, 1-6 online publication www.bjcancer.com.
10. Skinner S.R., Garland S.M., Stanley M.A., Pitts M., and Quin M.A. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26. MJA 188 (2008) 238-241
11. Kjaer S., Hogdall E., Frederiksen K., Munck C., Van Den Brule A., Svare E., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10 year period. Cancer Res 66 (2006) 10630-10636
12. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type6specific HPV testing in preclinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
13. Viscidi R.P., Kotloff K.L., Clayman B., Russ K., Shapiro S., and Shah K.V. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 4 (1997) 122-126
14. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody response following incident infection. J Infect Dis 181 (2000) 1911-1919
15. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroractivity to human papillomavirus (HPV) type 16,18or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 (2004) 324-327
16. Schwarz TF. Human papillomavirus (HPV) 16/18 L1 ASO4 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 24 months after vaccination in women up to age 55 years. EUROGIN 2007.
17. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus 16 and 18: follow up from a randomised control trial. Lancet 367 (2006) 1247-1255
18. Schwarz T; Correlation between serum & cervical mucose antibody levels EUROGIN 2007.
19. Schwarz T.F. An AS04-containing human papillomavirus 16/18 vaccine for prevention of cervical cancer is immunogenic and well tolerated in women 15-55 years old. J Clin Oncol 24 (2006) 1008
20. th International Papillomavirus Congress Bejing China 2007
21. Skinner R, Verheijen R, Martens M, Salieron J, Kittisak W et al. Estimating prior HPV 16/18 exposure by age group of women enrolled in phase III clinical trials of GSK4s HPV vaccine. EUROGIN 2007.
22. Cruickshank M, Teixeira J, Gall S, Raymundo R, Garland S et al. Efficacy and safety of GSK4s vaccine in women initially seropositive or seronegative for HPV-16/18 in a phase III trial. EUROGIN 2007.
23. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., et al. Effect of human papillomavirus 16/18 viruslike particle vaccine among young women with pre-existing infection: a randomized trial. JAMA 298 (2007) 743-753